Every therapy, drug or approach that is in place today to treat cancer had its start in a clinical trial. American Oncology Partner practices bring innovative treatment options to patients, close to home. By partnering with Sarah Cannon, a global leader in offering community-based clinical trials, we offer clinical trial options to patients across several locations within AON’s network of oncology practices.
Why participate in clinical trials?
Clinical trials are designed to evaluate the effectiveness of new treatment interventions. The objective of these clinical trials is to test new therapies in patients who have cancer. Patients participate in clinical trials for several reasons, including:
- The potential to benefit from a new drug or treatment procedure
- Improved management of symptoms resulting from treatment of cancer
- The opportunity to directly contribute to improving the understanding of how to treat a cancer and ultimately, benefit other patients
Patients who participate in clinical trials receive either a promising new treatment or the best available conventional treatment. If a new treatment option is proven to work, patients who are participating in the clinical trial will be among the first to benefit. While there is no guarantee that any treatment will be successful, clinical trials have been proven to offer some of the most effective cancer treatments currently available today.
Talk to your doctor to discuss your clinical trial options.
Search for a Clinical Trial
Cancer Type
Practice
Line of Therapy
Biliary Cancer, Bladder Cancer, Brain Cancer, Breast Cancer, Colon and Rectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian and Endometrial Cancer, Pancreatic Cancer, Prostate Cancer
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
MORE DETAILSMelanoma
A Randomized, Double-blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with Opdivo (Nivolumab) in Subjects with Treatment-naïve Unrespectable or Metastatic Melanoma
MORE DETAILSLung Cancer
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
MORE DETAILSMultiple Myeloma
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
MORE DETAILSLung Cancer, Colon and Rectal Cancer, Pancreatic Cancer
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
MORE DETAILSColon and Rectal Cancer
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
MORE DETAILSHematology and Blood Disorders
A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)
MORE DETAILSOvarian and Endometrial Cancer
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
MORE DETAILSLung Cancer
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
MORE DETAILS